Derazantinib—an orally bioavailable, multikinase inhibitor with potent pan-fibroblast growth factor receptor (FGFR) activity—has preliminary anti-tumour activity and a manageable safety profile in patients with unresectable or metastatic FGFR2 fusion-positive intrahepatic cholangiocarcinoma, according to a recent study.